Experimentally reduced liver LBP levels, either under standard or non-obesogenic conditions, exacerbate liver inflammation, fibrosis, and oxidative stress in non-alcoholic steatohepatitis (NASH) in mouse models and are correlated with human liver damage markers, indicating a potential role for liver LBP in promoting liver health and mitigating NASH progression [22]. Here, LBP is linked to metabolic dysfunction-associated steatohepatitis.